Maxx’s Top Stock for August 2021
7investing Lead Advisor Maxx Chatsko's Top Stock for August 2021 is building one of the most versatile technology platforms in genetic medicines. He thinks this under-the-radar stock has the best 10X...
The Mother of All Binary Events Might End in an…
Deciphera Pharmaceuticals is nearing the most important data readout in its history.
How Do You Value Biotech Stocks?
Pre-commercial drug developers don't have traditional fundamentals to analyze, but investors can estimate the likelihood of clinical development. 7investing Lead Advisors Simon Erickson checks in...
Maxx’s Top Stock for July 2021
7investing Lead Advisor Maxx Chatsko's Top Stock to buy in July 2021 is incorporating machine learning and artificial intelligence to enable true precision medicine.
RNAi is Setting a High Bar for Gene Editing
In the second quarter, three different RNAi drug candidates or drug products demonstrated the ability to reverse three different diseases.
What Makes a Biotech 10-Bagger?
You don't necessarily have to sift through microcaps. You do need to focus on the right metrics. Maxx Chatsko offers his perspective.
Maxx’s Top Stock for June 2021
7investing Lead Advisor Maxx Chatsko's Top Stock for June 2021 is well positioned to build solutions for some of the biggest obstacles facing the genetic testing markets.
Maxx’s Top Stock for May 2021
7investing Lead Advisor Maxx Chatsko's Top Stock for May 2021 is leading the energy transition to zero-carbon power sources and the electrification of transportation.
Can the Bioeconomy Transform Argentina into a Regional Superpower?
Maxx Chatsko notes that while all eyes are on Brazil, the geographic strengths of its southern neighbor cannot be overlooked.
AACR Annual Meeting 2021: What’s the Frontier of Cancer Research?
The American Association for Cancer Research (AACR) Annual Meeting 2021 begins this weekend. 7investing Lead Advisors Maxx Chatsko and Dan Kline discuss why the scientific meeting matters to...
Maxx’s Top Stock for April 2021
7investing Lead Advisor Maxx Chatsko's Top Stock to buy in April 2021 is developing a genetic medicine platform with several key advantages over peers.
The Many Paths to Portfolio Allocation
Investing is personal, but Maxx Chatsko points out the many ways you can handle portfolio allocation.
Maxx’s Top Stock for March 2021
Maxx's Top Stock for March 2021 is an enterprise software company driving the digital transformation of a massive global industry and saving customers billions of dollars.
What FinTwit Isn’t Telling You About These Biotech Stocks
When biotech stocks rise on stories alone, and those stories become detached from reality, then you might be subjecting your portfolio to unnecessary risk. 7investing Lead Advisors Manisha Samy and...
A Mission Statement is Easy. Execution is Difficult
A mission statement is nice to have, but it too often becomes a marketing pitch. Progress, including within a company's mission, is more important for investors.
Maxx’s Top Stock for February 2021
7investing Lead Advisor Maxx Chatsko's Top Stock for February is an early-stage biopharma attempting to fundamentally change drug discovery and drug development.
Genomics Isn’t the Only Omics
Maxx discusses misconceptions surrounding one of the market's oft-used buzzwords.
JPM 39th Annual Healthcare Conference: What We’re Watching
The JPM 39th Annual Healthcare Conference is next week. 7investing Lead Advisors Simon Erickson, Manisha Samy, and Maxx Chatsko discuss what they're watching as investors (and science nerds) ahead of...
Maxx’s Top Stock for January
7investing Lead Advisor Maxx Chatsko's top stock to buy in January 2021 is a small-cap biopharma developing an important technology platform that could increase the value of gene therapies, genetic...
Does the “B” Word Apply? It’s Complicated
Maxx Chatsko offers a glimpse into how he values development-stage biopharma stocks.
ASH Conference Preview: What We’re Watching
7investing lead advisors Manisha Samy and Maxx Chatsko share what they're watching at the upcoming American Society of Hematology annual conference.
Synthetic Biology’s “Window of Opportunity” with ConVergInce Advisers’ Joel Stone
Can synthetic biology break the chemical industry's reliance on fossil fuels? Industry veteran Joel Stone shares how industrial biotech is changing consumer brands, energy, agriculture, and more.
Maxx’s Top Stock for December
7investing lead advisor Maxx Chatsko's Top Stock for December is leading the energy transition, today and tomorrow.
Lesson Learned: Great Technology Doesn’t Guarantee a Great Business
Maxx explains the importance of separating promising technology from great business.
Maxx’s Top Stock for November
7investing lead advisor Maxx Chatsko's November 2020 recommendation is an under-the-radar, small-cap living technologies company at the very beginning of its growth trajectory.
Will the Cannabis Industry Give Way to Biotech?
7investing Lead Advisor Maxx Chatsko talks with Kevin Chen, co-founder and CEO of Hyasynth Bio, about the cannabis industry and how industrial biotech could transform the production of cannabinoid...
Not Another Political Discussion
Maxx argues why investors today would do well to zoom out for a bigger-picture view of the world.